<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Wiley</publisher>
				<availability status="unknown"><p>Copyright Wiley</p>
				</availability>
				<date type="published" when="2003-03-14">2003-03-14</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Frank</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre for Neuromuscular and Neurological Disorders</orgName>
								<orgName type="institution" key="instit1">University of Western Australia</orgName>
								<orgName type="institution" key="instit2">Elizabeth II Medical Centre</orgName>
								<address>
									<postCode>6009</postCode>
									<settlement>Nedlands</settlement>
									<region>Queen, Western Australia</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Neurology and Clinical Neurophysiology</orgName>
								<orgName type="institution">Sir Charles Gairdner Hospital</orgName>
								<address>
									<settlement>Nedlands</settlement>
									<region>Western Australia</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">School of Pharmacy</orgName>
								<orgName type="institution">Curtin University</orgName>
								<address>
									<settlement>Perth</settlement>
									<country>Australia, Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Beverley</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">School of Physiotherapy</orgName>
								<orgName type="institution">University of Melbourne</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MB</roleName><forename type="first">Paul</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Clinical Immunology</orgName>
								<orgName type="institution">Sir Charles Gairdner Hospital</orgName>
								<address>
									<settlement>Nedlands</settlement>
									<region>Western Australia</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">by University Of Illinois At Urbana Champaign</orgName>
								<address>
									<addrLine>Wiley Online Library on [06</addrLine>
									<country>03</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Inflammatory myopathies: Clinical, diagnostic and therapeutic aspects</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Muscle &amp; Nerve</title>
						<title level="j" type="abbrev">Muscle Nerve</title>
						<idno type="ISSN">0148-639X</idno>
						<idno type="eISSN">1097-4598</idno>
						<imprint>
							<publisher>Wiley</publisher>
							<biblScope unit="volume">27</biblScope>
							<biblScope unit="issue">4</biblScope>
							<biblScope unit="page" from="407" to="425"/>
							<date type="published" when="2003-03-14" />
						</imprint>
					</monogr>
					<idno type="MD5">11AC3777F807E591D99CC1E367C2BC25</idno>
					<idno type="DOI">10.1002/mus.10313</idno>
					<note type="submission">Accepted 23 October 2002</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>CK, creatine kinase</term>
					<term>CT, computerized tomography</term>
					<term>DM, dermatomyositis</term>
					<term>EMG, electromyography</term>
					<term>GNE, UDP-N-acetyl glucosamine 2-epimerase/N acetyl mannosamine kinase gene</term>
					<term>HIV, human immunodeficiency virus</term>
					<term>HLA, human leukocyte antigens</term>
					<term>HMG CoA, 3-hydroxy-3-methylglutaryl coenzyme A</term>
					<term>HTLV-1, human T-cell lymphotropic virus</term>
					<term>IBM, inclusionbody myositis</term>
					<term>ICAM-1, intercellular adhesion molecule-1</term>
					<term>IL, interleukin</term>
					<term>IL-1Ra, interleukin-1 receptor antagonist</term>
					<term>IVIg, intravenous immunoglobulin</term>
					<term>MCP-1, monocyte chemoattractant protein-1</term>
					<term>MCTD, mixed connective tissue disease</term>
					<term>MHC, major histocompatibility complex</term>
					<term>MIP-1␣, macrophage inflammatory protein-1␣</term>
					<term>MRI, magnetic resonance imaging</term>
					<term>nRNP, nuclear ribonucleoprotein</term>
					<term>PAS, periodic acid-Schiff</term>
					<term>PM, polymyositis</term>
					<term>RANTES, regulated-upon-activation normal T-cell expressed and secreted</term>
					<term>SLE, systemic lupus erythematosus</term>
					<term>SRP, signal recognition particle</term>
					<term>STIR, fat-suppressive sequences</term>
					<term>TGF-␤1, transforming growth factor-␤1</term>
					<term>TNF-␣, tumor necrosis factor-␣ clinical features</term>
					<term>dermatomyositis</term>
					<term>diagnosis</term>
					<term>inclusion-body myositis</term>
					<term>inflammatory myopathies</term>
					<term>polymyositis</term>
					<term>treatment</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The three major forms of immune-mediated inflammatory myopathy are dermatomyositis (DM), polymyositis (PM), and inclusion-body myositis (IBM). They each have distinctive clinical and histopathologic features that allow the clinician to reach a specific diagnosis in most cases. Magnetic resonance imaging is sometimes helpful, particularly if the diagnosis of IBM is suspected but has not been formally evaluated. Myositis-specific antibodies are not helpful diagnostically but may be of prognostic value; most antibodies have low sensitivity. Muscle biopsy is mandatory to confirm the diagnosis of an inflammatory myopathy and to allow unusual varieties such as eosinophilic, granulomatous, and parasitic myositis, and macrophagic myofasciitis, to be recognized. The treatment of the inflammatory myopathies remains largely empirical and relies upon the use of corticosteroids, immunosuppressive agents, and intravenous immunoglobulin, all of which have nonselective effects on the immune system. Further controlled clinical trials are required to evaluate the relative efficacy of the available therapeutic modalities particularly in combinations, and of newer immunosuppressive agents (mycophenolate mofetil and tacrolimus) and cytokine-based therapies for the treatment of resistant cases of DM, PM, and IBM. Improved understanding of the molecular mechanisms of muscle injury in the inflammatory myopathies should lead to the development of more specific forms of immunotherapy for these conditions.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PATHOGENESIS</head><p>Concepts of the pathogenic processes involved in the inflammatory myopathies have received considerable impetus from recent studies of their molecular immunology, immunohistochemistry, and immunogenetics. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b87">88,</ref><ref type="bibr" target="#b114">115,</ref><ref type="bibr" target="#b224">224</ref> These have further emphasized the role of the major histocompatibility complex (MHC) and other genetic factors, <ref type="bibr" target="#b224">224</ref> and have provided new insights into the humoral and cellular immune effector mechanisms including the role of cytokines, chemokines, and cell adhesion molecules, thereby identifying new potential therapeutic targets. In each of these conditions, inflammatory and immune mechanisms seem to play a role and each is characterized by T-cell and macrophage infiltrates (see below).</p><p>Although autoimmune responses are believed to be operative in at least DM and PM, target antigens have not been identified. In DM it has been established that the humoral immune process is directed against the vascular endothelium, with deposition of the C5b-9 membrane attack complex of complement, and leads to depletion of the endomysial capillary bed and ischemic muscle injury. <ref type="bibr" target="#b68">69,</ref><ref type="bibr" target="#b114">115,</ref><ref type="bibr" target="#b170">170</ref> However, neither the putative endothelial cell antibodies nor the autoantigens with which they interact have been characterized. A role for antibodies to the Mi antigen has not been defined and this autoantibody is not present in most patients with DM. <ref type="bibr" target="#b83">84</ref> Although intimate interaction between T-cells and muscle fibers has not been demonstrated in DM, close interaction between CD8 ϩ T-cells and nonnecrotic fibers has been consistently demonstrated in PM and IBM <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b114">115</ref> and intracellular polarization of perforin toward affected muscle fibers has been demonstrated in these invading T-cells. <ref type="bibr" target="#b94">95</ref> No specific T-cellreactive autoantigen has been defined in either disease and there is a paucity of evidence to support a role for the antigens recognized by the autoantibodies characteristic of PM (see below). In PM, restricted T-cell receptor V gene usage by invading T-cells suggests an antigen-specific reaction. <ref type="bibr" target="#b53">54,</ref><ref type="bibr" target="#b114">115</ref> In IBM, there is some debate as to whether the T-cell infiltrate represents a true antigen-driven autoimmune reaction <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b80">81,</ref><ref type="bibr" target="#b193">193</ref> although some recent data suggest limited T-cell receptor heterogeneity among muscle-invading T-cells. <ref type="bibr" target="#b23">24</ref> In PM, DM, and IBM, there is a great deal of evidence to suggest that T-cell products are involved in the pathogenic process. Expression of cytokines such as interleukin (IL)-1(␣ and ␤), IL-6, interferon-␥, lymphotoxin, and tumor necrosis factor-␣ (TNF-␣) has been demonstrated in mononuclear cells in affected muscles in each disease group. <ref type="bibr" target="#b133">134,</ref><ref type="bibr" target="#b134">135,</ref><ref type="bibr" target="#b142">143,</ref><ref type="bibr" target="#b168">168</ref> Collectively, these cytokines have a variety of functions that can contribute to local inflammatory responses and the generation or perpetuation of autoimmune responses and may act synergistically to damage muscle cells. <ref type="bibr" target="#b123">124</ref> These functions include Tcell activation, recruitment of lymphocytes and mononuclear phagocytes, stimulation of expression of MHC molecules on a variety of cell types, and direct damage to target cells. Furthermore, a variety of chemotactic and inflammatory chemokines has been demonstrated in affected muscle in inflammatory muscle diseases. These include IL-8, monocyte chemoattractant protein-1 (MCP-1), regulated-uponactivation normal T-cell expressed and secreted (RANTES), and macrophage inflammatory protein-1␣ (MIP-1␣). <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b138">139,</ref><ref type="bibr" target="#b142">143</ref> In many studies, expression of a range of cytokines that might serve to inhibit inflammation (e.g., transforming growth factor-␤, IL-10, IL-4) has also been described. <ref type="bibr" target="#b142">143,</ref><ref type="bibr" target="#b168">168</ref> Presumably, in these diseases, the balance is in favor of the continued inflammatory response. Therapy aimed at inhibiting proinflammatory cytokine expression (or effect) or enhancing inhibitory cytokines may be of value in these diseases.</p><p>Expression of the cytokines and chemokines mentioned above has been well-documented in mononuclear cells, but other cells within muscle also seem to contribute to their expression and presumably exacerbate the inflammatory reaction. Thus, muscle cells can express IL-6, TNF-␣, IL-15, and the chemokines MCP-1 and RANTES. <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b62">63,</ref><ref type="bibr" target="#b74">75,</ref><ref type="bibr" target="#b81">82,</ref><ref type="bibr" target="#b183">183,</ref><ref type="bibr" target="#b231">231</ref> Furthermore, endothelial cells can also express IL-1␣ and this has been demonstrated in blood vessels in idiopathic inflammatory myopathies. <ref type="bibr" target="#b144">145</ref> The expression of these proinflammatory cytokines may be upregulated by the action of mononuclear cellderived cytokines and thus contribute further to the inflammatory response.</p><p>A further consequence of this cytokine expression in muscle is the upregulation of cell surface antigens that contribute to T-cell emigration into muscle, T-cell adherence, and T-cell activation. Expression of adhesion molecules such as intercellular adhesion molecule-1 on endothelial cells and muscle fibers, MHC class I and class II antigens on muscle fibers and activated T-cells, and CD40 on muscle fibers has been demonstrated. <ref type="bibr" target="#b61">62,</ref><ref type="bibr" target="#b114">115,</ref><ref type="bibr" target="#b122">123,</ref><ref type="bibr" target="#b231">231</ref> CD40 interaction with CD40 ligand on T-cells can result in upregulation of inflammatory cytokine and chemokine expression by muscle cells. <ref type="bibr" target="#b231">231</ref> Muscle cells have also been shown to express a BB1-like costimulatory molecule which is more prominent in inflammatory myopathies. <ref type="bibr" target="#b21">22</ref> Myoblasts at least can present antigen to T-cells 86 so the expression of such costimulatory molecules in the presence of MHC antigens may facilitate antigen-specific T-cell activation by muscle cells. Fas expression by muscle cells, along with Fas ligand on infiltrating T-cells and macrophages, has been demonstrated in IBM and PM, <ref type="bibr" target="#b20">21</ref> although evidence for apoptotic activity in muscle fibers is less clear. <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b114">115</ref> In sporadic IBM, the nature of the T-cell response remains unclear. <ref type="bibr" target="#b9">10,</ref><ref type="bibr" target="#b17">18</ref> Intimate interaction between CD8, DR positive (i.e., activated) T-cells which express perforin and granzyme, has been shown, <ref type="bibr" target="#b114">115</ref> but evidence of antigen-specific autoimmunity is scarce. Deposition of the A␤ fragment of the amyloid precursor protein is a feature of affected muscle in IBM (see below) and it has been shown that muscle cells can secrete A␤. <ref type="bibr" target="#b9">10</ref> Interaction of A␤ with muscle cells in turn can stimulate IL-6 production by these cells, <ref type="bibr" target="#b18">19</ref> and its interaction with macrophages can induce TNF-␣ and IL-1 secretion. <ref type="bibr" target="#b164">165</ref> Thus A␤ may contribute to a positive feedback loop that exacerbates inflammation in affected muscle. The stimulus for excessive A␤ production in IBM is unknown, and whether this precedes inflammation, or vice versa, remains to be determined. <ref type="bibr" target="#b9">10</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CLINICAL ASPECTS</head><p>Epidemiology. There are differences in the age and gender distribution of the three major forms of inflammatory myopathy. <ref type="bibr" target="#b155">156</ref> Dermatomyositis may occur in childhood or adult life, whereas PM is rare in childhood and occurs mainly after the second decade of life. Both conditions are more common in females, whereas IBM is more common in males and occurs mainly over the age of 50 years. <ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b205">205,</ref><ref type="bibr" target="#b227">227</ref> Reported overall incidence rates for the autoimmune inflammatory myopathies have varied from 2.18 to 7.7 per million and prevalence rates from 10 to 63 per million in different studies. <ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b190">190,</ref><ref type="bibr" target="#b199">199</ref> There is little data on the relative incidence of the different forms of inflammatory myopathy and few studies have distinguished between PM and IBM. The prevalence of IBM has recently been reported to be 9.3 per million in Western Australia, with an age-adjusted prevalence of 35.3 per million over the age of 50 years. <ref type="bibr" target="#b205">205</ref> A prevalence of 4.3 per million has been reported in the Netherlands, but the authors of this study considered that this figure was probably an underestimate related to incomplete ascertainment. <ref type="bibr" target="#b12">13</ref> Genetics. A number of observations indicate that genetic factors play a part in the development of the inflammatory myopathies. <ref type="bibr" target="#b82">83,</ref><ref type="bibr" target="#b224">224</ref> The first is the occurrence of various forms of inflammatory myopathy, including DM, PM, IBM, and orbital myositis, in more than one member of the same family, and reports of DM and IBM in twins (see review by Shamim et al. <ref type="bibr" target="#b224">224</ref> ). In addition, a higher incidence of other autoimmune disorders has been reported in the first-degree relatives of patients with inflammatory myopathies. <ref type="bibr" target="#b92">93,</ref><ref type="bibr" target="#b244">244</ref> It is likely that multiple genes contribute to susceptibility. The strongest link is with human leukocyte antigen (HLA) genes, in particular DRB1*0301 and the linked allele DQA1*0501, which have been associated with each of the major forms of idiopathic inflammatory myopathy, including sporadic cases of IBM but not hereditary inclusion body myositis. <ref type="bibr" target="#b126">127</ref> One of the strongest associations reported is that between sporadic IBM and the ancestral haplotype marked by DR3 and C4A*Q0, pointing to a susceptibility locus within the MHC close to the class II region. <ref type="bibr" target="#b84">85,</ref><ref type="bibr" target="#b87">88,</ref><ref type="bibr" target="#b127">128</ref> DR4 has been associated with d-penicillamine-induced myositis. <ref type="bibr" target="#b32">33</ref> Within PM and DM, even stronger HLA associations with myositis-specific autoantibodies have been described, as is reviewed elsewhere. <ref type="bibr" target="#b83">84,</ref><ref type="bibr" target="#b115">116</ref> In Caucasians, DR3 is strongly associated with antibodies to Jo-1 (see below), whereas the presence of antibodies to Mi-2 in DM has been associated with an MHC haplotype marked by DR7/DR53/DQA1*0201. Further, the presence of a tryptophan at amino acid 9 of the DR␤ chain is even more strongly associated with antibodies to Mi-2, suggesting a role for this amino acid in epitope presentation. <ref type="bibr" target="#b171">171</ref> Other, less clear, associations between HLA genes and autoantibodies in inflammatory myopathy have been reported in other races. <ref type="bibr" target="#b83">84</ref> Genetic polymorphisms at other loci, such as those encoding TNF-␣ and interleukin-1 receptor antagonist (IL-1Ra), have been shown to be possible risk factors for juvenile inflammatory myopathy. <ref type="bibr" target="#b224">224</ref> The TNF-␣ association may be a consequence of linkage dysequilibrium in the MHC and may thus reflect the DR3 association. Alternatively, the increased potential to produce TNF-␣, which has been associated with the TNF-308A variant, may contribute to disease pathogenesis. <ref type="bibr" target="#b197">197</ref> Apolipoprotein ⑀4 and variants in the mtDNA D-loop region have been associated with sporadic IBM, <ref type="bibr" target="#b86">87,</ref><ref type="bibr" target="#b128">129</ref> but genetic variations in the amyloid precursor protein and prion protein genes have been excluded. <ref type="bibr" target="#b83">84,</ref><ref type="bibr" target="#b195">195</ref> The quadriceps-sparing form of hereditary inclusion body myopathy has recently been shown to be associated with mutations in the UDP-N-acetyl glucosamine 2-epimerase/N acetyl mannosamine kinase (GNE) gene <ref type="bibr" target="#b66">67</ref> but preliminary findings suggest that the gene is not involved in the pathogenesis of sporadic IBM (Z. Argov, personal communication).</p><p>Clinical Manifestations. The clinical features of the inflammatory myopathies have been described in previous reviews. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b49">50,</ref><ref type="bibr" target="#b70">71,</ref><ref type="bibr" target="#b154">155</ref> The onset is usually more acute and the rate of progression more rapid in DM than in PM. It is slowest in IBM, in which muscle weakness develops insidiously and the diagnosis may not be made for several years. <ref type="bibr" target="#b205">205</ref> Myalgias and muscle tenderness sometimes occur, particularly in cases of DM or overlap syndromes, and are also a feature of some forms of eosinophilic myositis and fasciitis, and of the recently described condition of macrophagic myofasciitis. <ref type="bibr" target="#b90">91</ref> Although diffuse, the weakness in DM and PM is usually more severe in the shoulder and pelvic girdle muscles. Weakness of the neck flexors is common, but in some cases there is also severe weakness of the neck extensors resulting in difficulty in holding the head up ("dropped head"; Fig. <ref type="figure" target="#fig_0">1A</ref>). In our experience, this has been encountered particularly in patients with myositis associated with scleroderma or mixed connective tissue disease (Fig. <ref type="figure" target="#fig_0">1A</ref>). Dysphagia due to involvement of the pharyngeal and esophageal muscles is also common, especially in IBM. <ref type="bibr" target="#b117">118,</ref><ref type="bibr" target="#b251">251</ref> Laryngeal involvement may occur in DM but is rare. Weakness of the respiratory muscles develops in some cases of severe PM or DM and, when severe, may necessitate assisted ventilation. <ref type="bibr" target="#b223">223</ref> In DM and PM, the pattern of muscle weakness is nonselective. By contrast, in IBM weakness and atrophy are first observed in the quadriceps femoris muscles in the lower limbs, leading to a propensity to falls that may be the presenting symptom, and in the forearm flexor muscles in the upper limbs; the findings are often asymmetric. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b206">206</ref> Early involvement of the flexor digitorum profundus muscles leads to a characteristic inability to maintain flexion of the distal phalanges when the patient is asked to grip the examiner's fingers. As the disease progresses, there is also involvement of the flexor digitorum sublimis and finger extensors, and a "swan-neck" deformity of the fingers and hyperextension of the thumb may develop (Fig. <ref type="figure" target="#fig_0">1B-D</ref>). In addition, there is also increasing involvement of more proximal muscle groups in the upper limbs and of other muscle groups in the lower limbs. The clinical phenotype is variable and, in some patients with IBM, there is a more proximal pattern of muscle involvement in both the upper and lower limbs from the outset, or purely upper or lower limb involvement. <ref type="bibr" target="#b136">137,</ref><ref type="bibr" target="#b162">163,</ref><ref type="bibr" target="#b206">206</ref> Extramuscular Manifestations. The characteristic skin rash of DM on the upper eyelids (heliotrope rash) and face, knuckles (Gottron's sign), elbows, neck, upper chest and shoulders (shawl sign) is vir- tually diagnostic of the condition and may precede the muscle weakness (Fig. <ref type="figure" target="#fig_1">2</ref>). <ref type="bibr" target="#b31">32</ref> In some patients, the rash is the dominant feature and weakness may be minor or absent (amyopathic dermatomyositis), although evidence of myositis may be found if electromyography and muscle biopsy are performed. <ref type="bibr" target="#b198">198</ref> Conversely, in some patients with DM, the skin changes are absent or inconspicuous at the time of presentation of the myopathy. Subcutaneous calcinosis occurs particularly in juvenile DM, but occasionally also in adult cases, and takes the form of nodules or plaques of calcification over the elbows, forearms, knuckles, axillae, or buttocks which may be painful and may ulcerate through the skin and become infected (Figs. <ref type="figure" target="#fig_1">1E, 2E and F</ref>). The association of scleromyxedema with inflammatory myopathy is uncommon and carries a poor prognosis in our experience. <ref type="bibr" target="#b102">103</ref> Thickening and induration of the skin of the extremities occurs in some forms of eosinophilic myositis such as the eosinophilia-myalgia syndrome, and Shulman's syndrome in which fasciitis is a prominent feature.</p><p>Involvement of other organs is more common in some subgroups of patients with inflammatory myopathy. For example, angiopathy involving the gastrointestinal tract, and at times other organs, is a serious complication of juvenile DM and may also occur in adult cases. <ref type="bibr" target="#b14">15</ref> Arthralgias and synovitis of small or large joints may occur in patients with DM or PM, even without an associated connective tissue disease. A deforming arthropathy of the proximal and distal interphalangeal joints occurs typically in patients with inflammatory myopathy and antisynthetase antibodies. <ref type="bibr" target="#b150">151</ref> Interstitial lung disease is also more likely to develop in DM or PM patients with anti-Jo-1 or other antisynthetase antibodies <ref type="bibr" target="#b96">97,</ref><ref type="bibr" target="#b151">152,</ref><ref type="bibr" target="#b237">237</ref> and antiendothelial cell antibodies, <ref type="bibr" target="#b60">61</ref> and in those with myositis associated with a connective tissue disease, and adversely affects the prognosis in such cases. <ref type="bibr" target="#b113">114</ref> Cardiac involvement, including myocarditis, pericarditis, arrhythmias, congestive cardiac failure, and an increased incidence of electrocardiographic abnormalities is well documented in PM and DM, but symptomatic involvement is rare. <ref type="bibr" target="#b63">64</ref> Associated Conditions. Overlap Syndromes. The reported frequency of other connective tissue diseases in patients with PM or DM has varied from 11-40% in different series. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b78">79,</ref><ref type="bibr" target="#b129">130</ref> The association is most frequent with scleroderma <ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b166">166</ref> and mixed connective tissue disease, <ref type="bibr" target="#b225">225</ref> and is rare in systemic lupus erythematosus (SLE), rheumatoid disease, and Sjo ¨gren's syndrome. <ref type="bibr" target="#b215">215,</ref><ref type="bibr" target="#b255">255</ref> Symptomatic myopathy resulting in proximal limb and neck muscle weakness has been reported to develop in up to 17% of patients with established scleroderma. <ref type="bibr" target="#b77">78,</ref><ref type="bibr" target="#b255">255</ref> More common is the occurrence of PM or DM in patients with other associated features such as acrosclerosis, Raynaud's phenomenon, and arthropathy ("scleroderma-myositis" overlap). A high proportion of such patients are positive for the PM-Scl antinucleolar antibody and carry the HLA-DQA1*0501 and DRB1*0301 allelic markers. <ref type="bibr" target="#b103">104,</ref><ref type="bibr" target="#b191">191</ref> Malignant Disease. The increased risk of malignancy in patients with DM was confirmed in casecontrol studies and meta-analyses, <ref type="bibr" target="#b112">113,</ref><ref type="bibr" target="#b252">252,</ref><ref type="bibr" target="#b253">253</ref> and was found to be greatest in patients over the age of 50 years. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b200">200</ref> These studies showed that the period of increased risk included the 4 years prior to diagnosis of DM as well as the 4 years following diagnosis, particularly the 1st year, and also applied to cases with skin involvement alone. <ref type="bibr" target="#b247">247</ref> By contrast, in PM, an increase was found only for the 1-5-year period after diagnosis of the myositis, which may have been due to increased surveillance and detection. <ref type="bibr" target="#b253">253</ref> These findings were confirmed in a recent population-based Australian study that found a sixfold increase in the risk of malignancy in DM and a twofold increase in PM, the risk diminishing progressively FIGURE 3. Proposed algorithm for treatment of polymyositis and dermatomyositis, modified from Mastaglia et al. <ref type="bibr" target="#b160">161</ref> with permission. AZA, azathioprine; CK, creatine kinase; IVIg, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; MTX, methotrexate.</p><p>during the 5-year period after diagnosis. <ref type="bibr" target="#b28">29</ref> Age over 45 years and male gender were found to be independent predictors of malignancy in a recent Asian study. <ref type="bibr" target="#b34">35</ref> The spectrum of malignancies associated with DM is similar to that in the general population, with breast and ovarian cancer being most common in females, and lung and gastrointestinal cancer in males. <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b246">246</ref> An association with nasopharyngeal cancer has been reported in Asian patients with DM. <ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b202">202</ref> Retroviral Infections. About one-third of patients with human immunodeficiency virus (HIV) infection develop a myopathy. <ref type="bibr" target="#b51">52</ref> This may be clinically and histologically indistinguishable from polymyositis. In some cases, inflammatory changes are inconspicuous and rod-bodies or cytoplasmic bodies are prominent in the muscle biopsy. The myopathy is characterized by the subacute onset of myalgia and proximal muscle weakness, and needs to be distinguished from the mitochondrial myopathy that may occur in patients treated with zidovudine. In addition, patients with immunodeficiency may develop various opportunistic muscle infections, and a progressive muscle wasting syndrome commonly occurs in patients with advanced disease.</p><p>Polymyositis may also occur in patients infected with the human T-cell lymphotropic virus (HTLV-1), either alone or in combination with a myelopathy (tropical spastic paraparesis). A high prevalence of HTLV-1-associated PM has been reported in Jamaicans <ref type="bibr" target="#b177">177</ref> and also occurs in other parts of the world such as Japan and the United States. <ref type="bibr" target="#b50">51</ref> Inclusion-body myositis has also been reported in association with HIV and HTLV-1 infection. <ref type="bibr" target="#b47">48</ref> Drug-Induced Myositis. A number of drugs have been associated with the development of an inflammatory myopathy, and in particular DM. However, drug-induced myositis accounts for only a small proportion of cases of inflammatory myopathy. The drugs that have been implicated include D-penicillamine, <ref type="bibr" target="#b32">33</ref> quinidine and procainamide, <ref type="bibr" target="#b130">131</ref> and some nonsteroidal antiinflammatory agents (e.g., niflumic acid). <ref type="bibr" target="#b99">100</ref> Several of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor group of hypocholesterolemic agents are known to cause a noninflammatory necrotizing myopathy <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b124">125,</ref><ref type="bibr" target="#b239">239</ref> but there are also some reports of an inflammatory myopathy developing in patients treated with simvastatin. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b93">94</ref> Polymyositis has been reported in some patients treated with interferon-␣ 182 and interleukin-2. <ref type="bibr" target="#b76">77</ref> Contaminated preparations of l-tryptophan were implicated in the outbreak of the eosinophiliamyalgia syndrome in the early 1990s. <ref type="bibr" target="#b22">23</ref> Other Varieties. Eosinophilic Myositis. An eosinophilic form of myositis which is clinically indistinguishable from the usual form of polymyositis may rarely occur. <ref type="bibr" target="#b131">132</ref> In some cases, the myositis is part of a systemic hypereosinophilic syndrome in which anemia, skin changes, cardiac and pulmonary involvement, and peripheral and central nervous system involvement may also occur. <ref type="bibr" target="#b131">132,</ref><ref type="bibr" target="#b209">209</ref> Other rare forms of eosinophilic myositis include eosinophilic fasciitis (Shulman's syndrome), <ref type="bibr" target="#b226">226</ref> eosinophilic perimyositis, and the eosinophilia-myalgia syndrome, <ref type="bibr" target="#b111">112</ref> which are characterized by widespread muscle pain and stiffness, and associated skin thickening and induration. <ref type="bibr" target="#b209">209</ref> Granulomatous Myositis. Granulomatous myopathy is rare. It is usually associated with systemic sarcoidosis but sometimes occurs in isolation <ref type="bibr" target="#b179">179,</ref><ref type="bibr" target="#b210">210</ref> and has also been reported in association with IBM. <ref type="bibr" target="#b59">60</ref> Granulomatous myopathy may also occur in patients with thymoma, when it may be associated with myasthenia gravis, myocarditis, thyroiditis, pancytopenia, and biliary cirrhosis. <ref type="bibr" target="#b110">111,</ref><ref type="bibr" target="#b185">185</ref> Other conditions that may be associated with granulomatous myopathy include Wegener's granulomatosis, <ref type="bibr" target="#b64">65</ref> rheumatoid disease, <ref type="bibr" target="#b110">111</ref> and Crohn's disease. <ref type="bibr" target="#b169">169</ref> Infectious causes of granulomatous myositis, such as tuberculosis and fungal infections, should always be considered and excluded by appropriate biopsy staining procedures and serological studies.</p><p>Macrophagic Myofasciitis. A form of inflammatory myopathy characterized by myalgias, arthralgias, fever, weakness,increased erythrocyte sedimentation rate, and endomysial and perimysial infiltration with periodic acid-Schiff (PAS)-positive macrophages and lymphocytes has recently been described with more than 130 cases in France and certain other countries. <ref type="bibr" target="#b37">38,</ref><ref type="bibr" target="#b90">91</ref> Macrophage inclusions have now been identified as deposits of aluminum hydroxide and the condition has been linked to the administration of aluminum hydroxide-containing vaccines. <ref type="bibr" target="#b91">92</ref> Pipestem Capillary Disease. This is a distinctive form of inflammatory necrotizing myopathy associated with marked hyalinization and thickening of capillary walls, capillary loss, and microvascular deposition of complement membrane-attack complex. <ref type="bibr" target="#b69">70</ref> Its nosological place remains uncertain, but a link to DM has been postulated and an association with malignancy has been reported in one case. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b69">70</ref> DIAGNOSTIC ASSESSMENT Confirmation of Diagnosis. The definitive diagnosis of an inflammatory myopathy requires a muscle biopsy. In some instances, however, the diagnosis can be made on clinical grounds, for example when the typical skin changes of DM are present, or can be suspected if the characteristic pattern of muscle involvement of IBM is found. The serum creatine kinase (CK) activity is usually elevated in patients with active disease, but the serum CK level may be normal or only mildly elevated particularly in DM, IBM, and in focal or interstitial forms of myositis.</p><p>Electromyography (EMG) allows confirmation of a myopathic process with the presence of early-recruiting motor unit potentials of low amplitude and short duration in the limb and paraspinal muscles, and will often also show prominent spontaneous muscle fiber potentials in patients with active myositis. However, the changes may be patchy and are nonspecific. In IBM, there may be both myopathic and neuropathic features, with some motor unit potentials of long duration, which may lead to a mistaken diagnosis of a neurogenic disorder such as motor neuron disease. <ref type="bibr" target="#b48">49</ref> Nerve conduction studies show evidence of a coexisting peripheral neuropathy in some cases. <ref type="bibr" target="#b106">107,</ref><ref type="bibr" target="#b121">122,</ref><ref type="bibr" target="#b135">136</ref> However, quantitative and macro-EMG studies have failed to confirm that there is a neurogenic component in most cases of IBM. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b140">141</ref> When the muscle biopsy is normal or shows only minor nonspecific changes, the diagnosis of inflammatory myopathy is problematic and greater emphasis then needs to be placed on clinical criteria and the results of other laboratory investigations. A number of attempts have been made to develop sets of diagnostic criteria for the inflammatory myopathies, taking into account clinical and pathological criteria as well the presence of myositis-specific autoantibodies and immunogenetic markers. <ref type="bibr" target="#b24">25,</ref><ref type="bibr" target="#b139">140,</ref><ref type="bibr" target="#b167">167,</ref><ref type="bibr" target="#b234">234,</ref><ref type="bibr" target="#b236">236</ref> The best known of these are the Bohan and Peter criteria, which were developed for PM and DM but did not include IBM. More specific diagnostic criteria for DM, PM, and IBM have recently been proposed. <ref type="bibr" target="#b155">156</ref> Muscle Imaging. It has been suggested that magnetic resonance imaging (MRI) or computerized tomographic (CT) scanning may be helpful in confirming the diagnosis of an inflammatory myopathy and determining its type, and in selecting an appropriate biopsy site. <ref type="bibr" target="#b198">198</ref> However, the diagnostic sensitivity of these imaging techniques has not been evaluated. The results of such studies may also be helpful and may guide therapeutic decisions when a biopsy is not possible or the biopsy findings are inconclusive. <ref type="bibr" target="#b79">80,</ref><ref type="bibr" target="#b213">213</ref> Although CT scanning is more sensitive for displaying subcutaneous or fascial calcification in DM, MRI is the modality of choice for detecting active myositis and recognizing selective patterns of muscle involvement in IBM. <ref type="bibr" target="#b206">206</ref> The characteristic finding in patients with active PM or DM consists of a multifocal or diffuse pattern of high signal intensity on T2-weighted fat-suppressive (STIR) or nonfat-saturated sequences, which is more marked in proximal limb muscles. <ref type="bibr" target="#b79">80,</ref><ref type="bibr" target="#b213">213,</ref><ref type="bibr" target="#b214">214</ref> Such changes may also be found in patients with amyopathic DM. <ref type="bibr" target="#b230">230</ref> With increasing disease duration, there is muscle atrophy and increased signal intensity on both T1and T2-weighted images, reflecting an increased adipose tissue content of the muscle. In IBM, there is, characteristically, selective involvement of the quadriceps femoris muscles in the thighs with relative sparing of the rectus femoris, and involvement of the medial gastrocnemius muscles and forearm flexor muscles. <ref type="bibr" target="#b206">206,</ref><ref type="bibr" target="#b222">222</ref> We have found this pattern of muscle involvement useful in supporting the diagnosis in patients with atypical clinical features or inconclusive muscle biopsy findings.</p><p>Muscle Biopsy. Muscle biopsy is the definitive diagnostic procedure and, when possible, should be performed before commencement of treatment. The biopsy will not only allow confirmation of the diagnosis of an inflammatory myopathy but will also provide some indication of the severity and type of myositis and allow recognition of rarer forms such as eosinophilic, granulomatous, or parasitic myositis. An open biopsy from the vastus lateralis, biceps brachii, or deltoid muscle is preferable to a needle biopsy as it provides a larger tissue sample and reduces the likelihood of sampling error. However, because of the patchy nature of the histological changes, the biopsy may be normal or inconclusive, particularly in DM. <ref type="bibr" target="#b196">196</ref> In some patients with the clinical features of IBM, the initial biopsy does not show the characteristic rimmed vacuoles and a diagnosis of possible IBM only will be made. <ref type="bibr" target="#b98">99</ref> Muscle MRI and isotope scintigraphy have been suggested as ways of selecting a biopsy site and reducing the problem of sampling error, but the value of these techniques has not been formally evaluated. <ref type="bibr" target="#b143">144</ref> A semi-open technique using a conchotome has also been advocated and is more suitable if it is planned to perform repeat biopsies to assess disease activity in clinical trials. <ref type="bibr" target="#b143">144</ref> The biopsy should not be taken from a muscle that is severely atrophic, or from a muscle on which needle electromyography has been performed previously as it may show changes of a "needle myopathy." Tissue should be obtained not only for conventional light microscopic examination but also for immunohistochemical studies (e.g., for T-cell sub-sets; HLA Class 1 antigen expression; amyloid deposition, ubiquitin, and SMI-31 immunoreactivity in IBM) and for electron microscopy which is necessary to identify the tubuloreticular endothelial cell inclusions of DM <ref type="bibr" target="#b14">15</ref> and the characteristic tubulofilamentous inclusions of IBM. <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b148">149</ref> Autoantibodies. Antibodies to nuclear or cytoplasmic constituents have been reported in patients with inflammatory myopathies. These are classified as myositis-specific (i.e., occurring only in patients with inflammatory myopathies), or myositis-associated (i.e., found in patients with inflammatory myopathy as well as other connective tissue diseases). <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b83">84,</ref><ref type="bibr" target="#b235">235</ref> The most common autoantibodies in PM are the antisynthetases directed against various aminoacyl tRNA synthetases, which have the potential to interfere with the protein synthetic mechanism in muscle fibers. The best known is anti-Jo-1 (anti-histidyl tRNA synthetase), which is strongly associated with the DR3, DRw52, and DQA1*0501 HLA haplotype. Anti-Jo-1 has a high specificity for the antisynthetase syndrome in which myositis is associated with interstitial lung disease, arthritis, Raynaud's phenomenon, and "mechanic's hands." <ref type="bibr" target="#b173">173</ref> Anti-Jo-1 antibody has also been associated with perimysial inflammatory changes and fragmentation in the muscle biopsy. <ref type="bibr" target="#b180">180</ref> Antibodies to the signal recognition particle (SRP) have been associated with severe, acute-onset PM responding poorly to treatment. Antibodies to the Mi-2 antigen are highly specific for DM and are present in high titers in up to 35% of cases, including some cases of juvenile DM. <ref type="bibr" target="#b83">84</ref> With the possible exception of anti-Jo-1, none of the other antibodies have been found to have a sufficient degree of specificity or sensitivity to be of diagnostic or prognostic value, or to be useful for predicting responsiveness to treatment or monitoring disease activity.</p><p>Antibodies to the PM-Scl nucleolar antigen complex (originally referred to as anti-PM-1) have been reported in a high proportion of white patients with the scleroderma-myositis overlap. Almost 50% of patients with the antibody have this overlap syndrome but some have PM or scleroderma alone. <ref type="bibr" target="#b103">104,</ref><ref type="bibr" target="#b191">191</ref> The anti-Ku antibody has a high specificity, but low sensitivity, for the scleroderma-myositis overlap syndrome in Japanese patients. <ref type="bibr" target="#b175">175</ref> High titers of antibodies to nuclear ribonucleoprotein (nRNP) are a diagnostic marker for mixed connective tissue disease (MCTD) in which there is an overlap between features of scleroderma, polymyositis, SLE, and rheumatoid arthritis. <ref type="bibr" target="#b83">84</ref> Antiproteasomal antibodies are found in a high proportion of patients with autoimmune myositis, SLE, and Sjo ¨gren's syndrome, and their titer has been found to correlate with disease activity. <ref type="bibr" target="#b75">76</ref> Antiendothelial cell antibodies are found in DM and in other types of inflammatory myopathy, and in one study were found to be markers for the presence of interstitial lung disease. <ref type="bibr" target="#b60">61</ref> Other non-disease-specific antibodies have been reported in patients with IBM, but myositis-specific antibodies such as anti-Jo-1 are only rarely found in this condition. <ref type="bibr" target="#b107">108,</ref><ref type="bibr" target="#b125">126</ref> A high incidence of monoclonal gammopathies has been found in some series of IBM cases. <ref type="bibr" target="#b56">57</ref> Screening for Malignancy. Adult patients with DM, and in particular those over the age of 50 years, should be thoroughly screened for the presence of an occult malignancy at the time of presentation and should be reassessed annually thereafter, or if there is a recrudescence of the DM while on treatment. Although the risk of an associated malignancy is lower in patients with PM, a similar approach is prudent in this group of patients. Screening investigations should include mammography, gynecological examination, and pelvic ultrasound in women, prostatic studies in men, and chest radiography in all cases. The need for additional investigations such as abdominal CT and endoscopic studies should be guided by the clinical assessment of the patient and whether there is any racial or genetic predisposition to a particular form of malignancy. For example, nasopharyngeal examination should be performed in Asian patients with DM, who have a higher risk of developing nasopharyngeal cancer. In patients with dysphagia, the possibility of an esophageal malignancy should always be considered and endoscopic and videofluoroscopic studies should be requested if there is any doubt that the dysphagia is due to the myositis.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TREATMENT</head><p>The treatment of the immune-mediated inflammatory myopathies is still largely empirical as there is only limited data from controlled clinical trials to allow an evidence-based approach. <ref type="bibr" target="#b40">41,</ref><ref type="bibr" target="#b153">154,</ref><ref type="bibr" target="#b189">189,</ref><ref type="bibr" target="#b242">242</ref> Treatment has traditionally relied upon the use of corticosteroids and immunosuppressive agents, whose actions on the immune system are largely nonselective, and more recently on other forms of immunomodulatory therapy such as intravenous immunoglobulin. <ref type="bibr" target="#b52">53</ref> Recent experimental approaches which hold promise for the treatment of resistant cases include cytokine-directed therapies and the use of monoclonal antibodies targeting B-cells and T-cells involved in the immune response. More specific immunother-apy awaits a better understanding of the effector mechanisms and the identification of the target antigens against which the immune response is directed.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Polymyositis and Dermatomyositis. Corticosteroids.</head><p>Although they have never been evaluated in controlled clinical trials, corticosteroids remain the firstline therapy of choice for the treatment of both PM and DM, and their efficacy is well-established in clinical practice. In retrospective studies, 60 -70% of patients were found to respond to treatment and to achieve a complete or worthwhile remission. <ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b108">109,</ref><ref type="bibr" target="#b109">110,</ref><ref type="bibr" target="#b216">216,</ref><ref type="bibr" target="#b233">233</ref> It is important that the initial treatment regimen should be individualized in each patient, taking into account the duration and severity of the disease, associated prognostic factors and other disorders, as well as risk factors for adverse drug effects. In most cases, we recommend starting with oral prednisone (or prednisolone) in a daily dose of ϳ1 mg/kg. This should be continued for a period of 4 -6 weeks before tapering by 5-10 mg/ week, and conversion to an alternate-day regimen can reduce the risk of adrenal suppression and other steroid side effects, including steroid myopathy (Fig. <ref type="figure">3</ref>). <ref type="bibr" target="#b157">158,</ref><ref type="bibr" target="#b256">256</ref> The rate of tapering should not be too rapid and should also be individualized, taking into account the rate of clinical improvement and concern about side effects. Higher initial doses of prednisone and more prolonged periods of high-dose administration should be avoided as serious side effects are more likely to develop and may adversely affect the outcome in our experience.</p><p>It is preferable in some patients, and particularly those with severe myositis or in whom diagnosis was unduly delayed, to commence treatment with prednisone in combination with a steroid-sparing agent such as methotrexate or azathioprine. Combined therapy has been shown to be associated with a lower relapse rate <ref type="bibr" target="#b161">162,</ref><ref type="bibr" target="#b176">176</ref> and a better long-term outcome. <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b30">31</ref> The risk of disturbing diabetic control or of aggravating postmenopausal osteoporosis can be reduced by using a lower starting dose of prednisone (ϳ0.5 mg/kg/day) in combination with methotrexate or azathioprine. A retrospective review showed a similar outcome in patients treated with high (Ͼ0.5 mg/kg) and low daily doses (Ͻ0.5 mg/kg) of prednisone. <ref type="bibr" target="#b187">187</ref> Pulse Steroid Therapy. The relative efficacy of intermittent high-dose pulse therapy with corticosteroids has not been investigated in controlled clinical trials. However, in retrospective studies, initial pulse therapy with intravenous methylprednisolone was found to be associated with a higher remission rate and more rapid normalization of serum CK activity than oral therapy alone in adult PM and DM, <ref type="bibr" target="#b163">164</ref> and with more rapid disease control in juvenile DM. <ref type="bibr" target="#b118">119</ref> It has also been recommended as being preferable to oral therapy for ongoing administration in severely disabled elderly patients with DM. <ref type="bibr" target="#b89">90</ref> Pulse intravenous methylprednisolone may therefore be useful to obtain more rapid control in patients with severe myositis, or extramuscular manifestations such as interstitial lung disease or gastrointestinal angiopathy, in combination with ongoing oral prednisone and a steroid-sparing agent such as methotrexate or azathioprine. Pulse therapy with dexamethasone has also been claimed to be effective in an uncontrolled trial but requires further evaluation. <ref type="bibr" target="#b240">240</ref> Corticosteroid Myopathy. Steroid myopathy should be suspected when there is persisting or increasing weakness, particularly of proximal lower limb muscles, after the serum CK level has declined or normalized. When the weakness is due to a steroid myopathy, it will usually improve if the dose of prednisone is gradually reduced or an alternate-day regimen is instituted. However, it is sometimes unclear whether increasing muscle weakness is due to active myositis, steroid myopathy, or a combination of the two, and it may be necessary to repeat the electromyographic studies and muscle biopsy. A regular exercise program may help to at least partially prevent or reverse steroid myopathy. <ref type="bibr" target="#b116">117</ref> Relapses. Clinical relapses occur in a substantial proportion of cases of PM and DM. <ref type="bibr" target="#b204">204,</ref><ref type="bibr" target="#b232">232</ref> Although some relapses occur during withdrawal of prednisone or immunosuppressive therapy, in our experience the majority occur in patients who are on steady maintenance therapy or who are off treatment and in remission. <ref type="bibr" target="#b208">208</ref> When relapses occur, we recommend reinstituting daily prednisone in a dose of ϳ50 mg/day (0.7 mg/kg) for a few weeks. In more severe relapses, we also recommend starting methotrexate or azathioprine, or intravenous immunoglobulin in patients who are already taking an immunosuppressive agent (see below).</p><p>Steroid-Resistant Cases. Although most patients with PM or DM respond satisfactorily to corticosteroids, in 20 -30% of cases the response is slow or incomplete and it is then necessary to introduce a second-line agent (Fig. <ref type="figure">3</ref>) and to reduce the dose of prednisone. Methotrexate and azathioprine have both been shown to be effective in steroid-resistant cases in open studies and case reports, but the response is slow and variable. <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b211">211,</ref><ref type="bibr" target="#b241">241</ref> Few studies have evaluated the comparative efficacy of the two drugs. In one retrospective study, methotrexate was found to be superior to azathioprine in male patients and those with antisynthetase antibodies. <ref type="bibr" target="#b119">120</ref> In a recent double-blind comparative trial of methotrexate and azathioprine, the two drugs had equal efficacy but methotrexate had a more favorable side-effect profile. <ref type="bibr" target="#b172">172</ref> Methotrexate has the advantage that it can be given orally in a single weekly dose, and may also be administered by the intramuscular route if gastrointestinal side effects preclude oral use. <ref type="bibr" target="#b243">243</ref> If the response to methotrexate is poor, we recommend adding azathioprine, as the combination of the two drugs is more effective than either alone in some patients. <ref type="bibr" target="#b243">243</ref> In patients who fail to improve, we use intravenous immunoglobulin therapy (IVIg) or another immunosuppressive agent such as cyclophosphamide, cyclosporine, or mycophenolate mofetil.</p><p>Other Cytotoxic Agents. The only reports of the use of cyclophosphamide in the inflammatory myopathies are based on small open studies and case reports, and the results have been variable. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b45">46</ref> As the major effects of cyclophosphamide are on Bcells, <ref type="bibr" target="#b238">238</ref> the drug may be better suited for the treatment of resistant cases of DM, particularly if there is associated vasculitis. <ref type="bibr" target="#b97">98</ref> We favor cyclophosphamide over cyclosporine in such cases and in patients with myositis and associated interstitial lung disease, who are usually resistant to corticosteroids and other immunosuppressive agents. Although the drug can be given by the oral route, in our experience, intravenous pulse therapy is as effective and causes fewer side effects.</p><p>Cyclosporine has a more selective effect on T-cell activation and cytokine production by helper-inducer T-cells. <ref type="bibr" target="#b67">68</ref> Although there are no reports of controlled trials in the literature, a number of small open studies and case reports indicate that the drug can be effective in steroid-dependent cases of juvenile DM and in some adult PM or DM patients, including cases with associated interstitial lung disease. <ref type="bibr" target="#b104">105,</ref><ref type="bibr" target="#b141">142,</ref><ref type="bibr" target="#b145">146,</ref><ref type="bibr" target="#b149">150,</ref><ref type="bibr" target="#b186">186,</ref><ref type="bibr" target="#b212">212,</ref><ref type="bibr" target="#b254">254</ref> Our current practice is to reserve cyclosporine for patients with PM or DM who have failed to respond adequately to corticosteroids and to other immunosuppressive agents, and in whom IVIg has already been tried or is contraindicated. Tacrolimus, which also inhibits the activation of CD4 ϩ T helper cells, has been effective in a small group of patients with refractory polymyositis and associated interstitial lung disease with antisynthetase antibodies and warrants further evaluation. <ref type="bibr" target="#b192">192</ref> Mycophenolate mofetil has been reported to be effective in some resistant cases of PM and DM and also in severe myasthenia gravis. <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b88">89,</ref><ref type="bibr" target="#b221">221</ref> Although there have not as yet been any controlled trials, these initial reports have been promising both in terms of efficacy and side-effect profile and suggest that a trial of the drug is worth considering even before cyclophosphamide or cyclosporine in resistant cases. Fludarabine has also been found to be effective in some refractory cases of PM and DM and warrants further evaluation. <ref type="bibr" target="#b1">2</ref> Intravenous Immunoglobulin. Intravenous immunoglobulin therapy has been shown to be effective in cases of drug-resistant DM in a double-blind crossover trial. <ref type="bibr" target="#b55">56</ref> Improvement in muscle function was shown to correlate with reduced deposition of complement (C5b-9) in endomysial capillaries and downregulation of MHC-1, intercellular adhesion molecule-1 (ICAM-1), and transforming growth factor-␤1 (TGF-␤1) expression in muscle biopsies <ref type="bibr" target="#b52">53,</ref><ref type="bibr" target="#b55">56,</ref><ref type="bibr" target="#b58">59</ref> as well as a decline in serum levels of soluble interleukin-2 receptor (sIL-2R). <ref type="bibr" target="#b95">96</ref> IVIg has also been shown to be effective as add-on therapy in open studies in patients with PM, DM, and overlap syndromes. <ref type="bibr" target="#b35">36,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b95">96,</ref><ref type="bibr" target="#b159">160</ref> However, IVIg is not effective in all cases <ref type="bibr" target="#b95">96,</ref><ref type="bibr" target="#b159">160</ref> and did not suppress disease activity when used as first-line therapy without corticosteroids. <ref type="bibr" target="#b36">37</ref> We recommend IVIg in patients with DM in whom the myositis remains active despite corticosteroids, methotrexate, and azathioprine, and also in resistant cases of PM and overlap syndromes, although the evidence for its efficacy in such cases is less convincing. We also recommend IVIg in patients who are unable to continue immunosuppressive agents because of adverse effects, and in patients with immunodeficiency in whom such agents may be contraindicated.</p><p>New Therapies. More specific forms of therapy targeting proinflammatory cytokines (e.g., TNF-␣ and IL-1␤), T-and B-cells and their receptors and signaling pathways, and cell adhesion molecules (e.g., integrins, matrix metalloproteinases) hold promise for the treatment of resistant cases of inflammatory myopathy. <ref type="bibr" target="#b54">55</ref> There have been a number of preliminary reports of the successful use of anti-TNF-␣ therapy with infliximab (Remicaide) <ref type="bibr" target="#b105">106,</ref><ref type="bibr" target="#b147">148,</ref><ref type="bibr" target="#b188">188</ref> and etanercept (Enbrel) <ref type="bibr" target="#b219">219</ref> in resistant cases of juvenile and adult DM and PM. More formal evaluation of these agents in controlled clinical trials is now underway, and trials of T-and B-cell monoclonal antibodies are in the planning stages (M. Dalakas, personal communication). Interferon ␤-1a has also been reported to be effective in PM and warrants further evaluation. <ref type="bibr" target="#b65">66</ref> Inclusion-Body Myositis. Resistance to treatment with conventional forms of immunotherapy is one of the characteristic features of IBM that distinguishes it from the other inflammatory myopathies. <ref type="bibr" target="#b194">194</ref> Although occasional patients do respond to treatment with prednisone and immunosuppressive agents, at times dramatically, <ref type="bibr" target="#b107">108</ref> even in such cases the response is usually incomplete and not sustained. <ref type="bibr" target="#b107">108,</ref><ref type="bibr" target="#b132">133,</ref><ref type="bibr" target="#b220">220</ref> It is not known whether there are subgroups of IBM patients who are more likely to respond to treatment, and how these can be identified. However, there have been a number of case reports of a favorable response to corticosteroid and immunosuppressive therapy in patients with an associated autoimmune disease, and to immunoabsorption in a case with an associated monoclonal gammopathy. <ref type="bibr" target="#b184">184</ref> A favorable response to mycophenolate has been reported in one case. <ref type="bibr" target="#b178">178</ref> However, in most cases of IBM, there is continued deterioration, <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b201">201,</ref><ref type="bibr" target="#b217">217</ref> in spite of the fact that the treatment reduces muscle inflammation and T-cell invasion of muscle fibers. <ref type="bibr" target="#b17">18</ref> The efficacy and safety profile of a humanized monoclonal antibody to C5 complement in patients with DM is also being evaluated. <ref type="bibr" target="#b73">74</ref> There have been a number of open studies of IVIg therapy, some finding improved function in less affected muscle groups, <ref type="bibr" target="#b159">160,</ref><ref type="bibr" target="#b228">228</ref> whereas others reported no improvement. <ref type="bibr" target="#b4">5</ref> In a short-term placebocontrolled trial of IVIg in 19 patients, 58 some experienced mild functional benefit but no significant improvement occurred in overall muscle strength. In a subsequent placebo-controlled trial of IVIg with prednisone, no beneficial effects were demonstrated. <ref type="bibr" target="#b58">59</ref> In another placebo-controlled crossover study of 22 patients who received monthly IVIg for 6 months, apparent stabilization of the condition occurred in the majority of patients and mild improvement in a minority. <ref type="bibr" target="#b245">245</ref> However, it appears from the results of these studies that any benefits from IVIg are likely to be modest and, at best, temporary. IVIg has been reported to have longer lasting effects in some patients <ref type="bibr" target="#b181">181</ref> and sometimes to be beneficial in those with severe life-threatening dysphagia. <ref type="bibr" target="#b39">40</ref> Intravenous antithymocyte globulin in combination with methotrexate was shown to halt disease progression in a small uncontrolled study <ref type="bibr" target="#b137">138</ref> and warrants further evaluation.</p><p>New therapeutic strategies such as the use of interferon ␤ and cytokine-blocking agents also warrant testing in further controlled clinical trials. A recent 6-month placebo-controlled trial of interferon ␤-1a (30 g per week) failed to show any benefit. <ref type="bibr" target="#b101">102</ref> A further trial using a higher dose regimen is currently underway (Griggs and Tawil, personal communication).</p><p>Empirical forms of treatment include coenzyme Q 10 , carnitine, and antioxidants. <ref type="bibr" target="#b71">72</ref> One placebo-con-trolled trial of the synthetic testosterone analogue oxandrolone failed to show any significant improvement in muscle strength. <ref type="bibr" target="#b218">218</ref> The nonsteroidal anabolic agent clenbuterol has resulted in disease stabilization in some of our patients who have been assessed with serial quantitative muscle testing (Mastaglia et al., unpublished observation) and warrants further evaluation in a controlled clinical trial.</p><p>In the absence of evidence that any currently available form of therapy alters the natural history of the disease, there are no firm guidelines for the treatment of IBM, and views differ as to whether a trial of corticosteroid and immunosuppressive therapy should be recommended. <ref type="bibr" target="#b160">161,</ref><ref type="bibr" target="#b194">194</ref> Our current practice is to recommend a trial of prednisone (ϳ0.6 mg/kg) and a steroid-sparing agent such as methotrexate (starting at 10 mg/week) or azathioprine (1.5-2.5 mg/kg/day), provided that such treatment is not contraindicated by the patient's general medical condition and that the disorder is not too advanced. We avoid higher doses of prednisone because of the potential risk of inducing a steroid myopathy and further aggravating the muscle weakness. After commencement of treatment, the patient is monitored frequently and serial quantitative muscle testing is carried out. With improvement or stabilization of muscle strength, the dose of prednisone is gradually tapered and maintenance doses of the medications are continued. If muscle strength continues to deteriorate or side effects develop, the treatment is stopped.</p><p>Exercise Therapy. Exercise programs to improve muscle strength, endurance, and cardiovascular fitness have been used in the management of patients with various forms of myopathy, <ref type="bibr" target="#b203">203</ref> but few studies examining the efficacy of such programs in inflammatory myopathy have been reported. The types of exercise that may be included in strength training programs include isometric, isotonic, and isokinetic (either concentric or eccentric) exercise. An increase in isometric torque and an improvement in functional activities was reported in five patients with IBM following a 12-week isotonic training program for the knee extensors and flexors and the elbow and wrist flexors. <ref type="bibr" target="#b229">229</ref> In another study of five patients with acute PM or DM, there was an increase in strength following a program that included nonresisted exercise, manually resisted exercise, cycling, and stepping. <ref type="bibr" target="#b72">73</ref> In addition to muscle weakness, a reduced aerobic capacity compared to matched controls has been reported in inflammatory myopathy. <ref type="bibr" target="#b249">249</ref> A 6-week aerobic training program using a cycle ergometer resulted in a significant improve-ment in aerobic capacity and exercise tolerance in patients with PM or DM, and there was also an improvement in the isometric strength of the hip flexors and knee extensors and in a functional assessment scale. <ref type="bibr" target="#b248">248</ref> There has previously been some concern that active resisted exercise, particularly eccentric exercise, would increase muscle damage in inflammatory myopathy. It has been shown that any rise in the serum CK level immediately post-exercise is transient and followed by a return to baseline levels. <ref type="bibr" target="#b72">73,</ref><ref type="bibr" target="#b229">229,</ref><ref type="bibr" target="#b248">248</ref> In IBM patients, there were no consistent changes in the extent of inflammatory infiltrates in open muscle biopsies performed pre-and post-exercise. <ref type="bibr" target="#b229">229</ref> In a pilot study that included two patients with IBM, increasing the number of repetitions of a resisted (30% of maximum torque) isotonic exercise improved strength in some muscles, but when the weight used was gradually increased over 6 weeks, muscle strength declined, possibly as a result of minor muscle damage caused by the eccentric lowering of the heavier weight. <ref type="bibr" target="#b207">207</ref> These results indicate that carefully prescribed resisted strength and aerobic training programs may be undertaken safely by patients with active inflammatory myopathy. <ref type="bibr" target="#b146">147</ref> Further research is needed to determine the optimal training protocols, but both resisted strength training and aerobic training programs may be of benefit to patients with inflammatory myopathy and may assist in counteracting the effects of both a reduced activity level and the administration of highdose corticosteroids. Improvement or maintenance of muscle strength, endurance, and cardiovascular fitness will have a positive effect on the ability of patients to be active and independent in daily life.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessing Response to Treatment and Disease Activity.</head><p>Evaluating the response to treatment and activity of the myositis requires reliable clinical and laboratory criteria and, when available, should include some quantitative measures of muscle strength and endurance <ref type="bibr" target="#b157">158,</ref><ref type="bibr" target="#b158">159</ref> in addition to conventional manual muscle testing and MRC grading, which is relatively insensitive to change. Myometry using a hand-held instrument or computerized isokinetic dynamometry of selected muscle groups is suitable for the serial assessment of muscle function, particularly in clinical trials. In addition, the assessment protocol should ideally include some timed functional tests (e.g., time taken to stand up from a standard chair 10 times; time to walk 30 meters), functional scales, and tests of endurance, which are more pertinent to the performance of everyday activities. <ref type="bibr" target="#b46">47,</ref><ref type="bibr" target="#b120">121,</ref><ref type="bibr" target="#b157">158,</ref><ref type="bibr" target="#b250">250</ref> Protocols for the assessment of disease activity and outcome in adult and juvenile myositis have recently been proposed. <ref type="bibr" target="#b100">101,</ref><ref type="bibr" target="#b174">174</ref> Ventilatory function studies should be performed in patients with severe disease who may have weakness of the respiratory muscles.</p><p>Although previous studies have reached conflicting conclusions about the relationship between the serum CK level and disease activity, <ref type="bibr" target="#b157">158</ref> the CK level remains the most reliable biochemical indicator of disease activity in the individual patient, provided that it is elevated to start with, and should be monitored at regular intervals (e.g., every 1-3 months) after starting treatment. The serum CK level usually starts to decline before clinical improvement occurs, but mild to moderate elevations may persist for some time even after the patient has made a functional recovery. <ref type="bibr" target="#b157">158</ref> A rising serum CK level may be the first indication of disease reactivation in treated patients who have been in remission, even before muscle weakness develops. <ref type="bibr" target="#b157">158</ref> A number of studies have demonstrated normalization of MRI changes with clinical improvement and a good correlation between T2 and STIR signal intensity, and disease activity and muscle function. <ref type="bibr" target="#b79">80,</ref><ref type="bibr" target="#b214">214</ref> In addition, with 31 P magnetic resonance spectroscopy, it is possible to monitor the metabolic changes in muscle during treatment. <ref type="bibr" target="#b198">198</ref> Although such studies may be valuable for the serial assessment of responses to treatment in clinical trials, their routine use to monitor the response to treatment is unnecessary.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc>FIGURE 1. (A) "Dropped head" in patient with sclerodermamyositis overlap. (B-D) Deformity of fingers (B), and weakness of finger flexors (C) and extensors (D), in patients with advanced inclusion-body myositis (IBM). (E) Technetium pyrophosphate scan showing multifocal subcutaneous calcinosis of the arms in a patient with juvenile dermatomyositis.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc>FIGURE 2. Dermatomyositis rash on the face (A), chest (B), and hands (C-E). (E,F) Subcutaneous calcinosis.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Proposed classification of idiopathic inflammatory myopathies.</figDesc><table><row><cell>I</cell><cell>Dermatomyositis</cell></row><row><cell></cell><cell>Juvenile</cell></row><row><cell></cell><cell>Adult</cell></row><row><cell>II</cell><cell>Polymyositis</cell></row><row><cell></cell><cell>T-cell mediated (␣/␤, ␥/␦)</cell></row><row><cell></cell><cell>Eosinophilic</cell></row><row><cell></cell><cell>Granulomatous</cell></row><row><cell>III</cell><cell>Overlap syndromes</cell></row><row><cell></cell><cell>With polymyositis</cell></row><row><cell></cell><cell>With dermatomyositis</cell></row><row><cell></cell><cell>With inclusion-body myositis</cell></row><row><cell>IV</cell><cell>Cancer-associated myositis</cell></row><row><cell>V</cell><cell>Inclusion-body myositis</cell></row><row><cell>VI</cell><cell>Other forms</cell></row><row><cell></cell><cell>Focal: orbital myositis; localized nodular myositis;</cell></row><row><cell></cell><cell>inflammatory pseudotumor</cell></row><row><cell></cell><cell>Diffuse: macrophagic myofasciitis; necrotizing myopathy</cell></row><row><cell></cell><cell>with pipestem capillaries; infantile myositis</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="10974598" xml:id="foot_0">, 2003, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/mus.10313 by University Of Illinois At Urbana Champaign, Wiley Online Library on [06/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1">MUSCLE &amp; NERVE April 2003 10974598, 2003, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/mus.10313 by University Of Illinois At Urbana Champaign, Wiley Online Library on [06/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The authors acknowledge financial support from the Neuromuscular Foundation of Western Australia, and the secretarial support of Mrs. S. Moncrieff.</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The predominance of beta (CC) chemokine transcripts in idiopathic inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kirkley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eidelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dohlman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Assoc Am Physicians</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="275" to="285" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">A pilot study: use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pucino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yarboro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Thornton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mcgarvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Sonies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Bartlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Villalba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fleisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="352" to="360" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Elevated cancer incidence in patients with dermatomyositis: a population based study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Airio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pukkala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Isomaki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1300" to="1303" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurol Clin</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="615" to="648" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: treatment with intravenous immunoglobulin</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Pappert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sahenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Kissel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">444</biblScope>
			<biblScope unit="page" from="1516" to="1518" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: clinical and pathological boundaries</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Gronseth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">I</forename><surname>Wolfe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Bryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="581" to="586" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies: III. Immunoelectronmicroscopy aspects of cell-mediates muscle fibre injury</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="112" to="125" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Drug-induced myopathies</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Argov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="541" to="545" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Drug-induced neuromuscular disorders in man</title>
		<author>
			<persName><forename type="first">A</forename><surname>Argov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Disorders of voluntary muscle</title>
				<editor>
			<persName><forename type="first">J</forename><surname>Walton</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Hilton-Jones D</forename></persName>
		</editor>
		<meeting><address><addrLine>Edinburgh</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1994">1994</date>
			<biblScope unit="page" from="989" to="1029" />
		</imprint>
		<respStmt>
			<orgName>Churchill Livingstone</orgName>
		</respStmt>
	</monogr>
	<note>6th ed</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Does overexpression of bAPP in aging muscle have a pathogenic role in a relevance to Alzheimer&apos;s disease: clues from inclusion body myositis, cultured human muscle and transgenic mice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">153</biblScope>
			<biblScope unit="page" from="1673" to="1677" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="389" to="391" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Necrotizing myopathy with pipestem capillaries and minimal cellular infiltration: a case associated with cutaneous signs of dermatomyositis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Authier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kondo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Ghnassia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Revuz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gherardi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1448" to="1451" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Epidemiology of inclusion body myositis in the Netherlands: a nationwide study</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Badrising</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maat-Schieman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Van Duinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Van Doorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hoogendijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Howeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>De Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jennekens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Van Der Leeuw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Verschuuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Wintzen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="1385" to="1387" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Badrising</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maat-Schieman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Zwinderman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jam</forename><surname>Wessels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Breedveld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Van Doorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bgm</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hoogendijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Howeler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fgi</forename><surname>Jennekens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Koehler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Viddeleer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Verschuuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Wintzen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="369" to="372" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Ultrastructural alterations of muscle and intramuscular blood vessels</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="46" to="75" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
	<note>Dermatomyositis of childhood</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Quantitative electrophysiologic studies in sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Barkhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Periquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Nandedikar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="480" to="487" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Dermatomyositis and malignancy</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="68" to="76" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: explanation for poor response to therapy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Barohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sahenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Kissel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="1302" to="1304" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Production of IL-6 by human myoblasts stimulated with A␤ relevance in the pathogenesis of IBM</title>
		<author>
			<persName><forename type="first">P</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Galimberti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Meda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Scarpini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Conti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cogiamanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Scarlato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1561" to="1565" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Constitutive and cytokine-induced production of interleukin-6 by human myoblasts</title>
		<author>
			<persName><forename type="first">E</forename><surname>Bartoccioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunol Lett</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="135" to="138" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibers and inflammatory cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="929" to="938" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Human muscle cells express a functional costimulatory molecule distinct from B7.1 (CD80) and B7.2 (CD86) in vitro and in inflammatory lesions</title>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kerschensteiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Misgeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="5943" to="5951" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Belongia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Hedberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Gleich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Mayeno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Loegering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Dunnette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Pirie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Osterholm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">323</biblScope>
			<biblScope unit="page" from="357" to="365" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">T-cell heterogeneity in muscle lesions of inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="86" to="91" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Peter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">292</biblScope>
			<biblScope unit="page" from="344" to="347" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A computerassisted analysis of 153 paients with polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Peter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Bowman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Pearson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="255" to="286" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Cyclophosphamide in severe polymyositis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bombardieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grv</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Neri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Bravo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Bono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1138" to="1139" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Autoantibody profiles in the sera of European patients with myositis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Brouwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gjd</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">V</forename><surname>Egberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ehrfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chirardello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Grondal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hietarinta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Isenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Kalden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lundbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Moutsopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Roux-Lombard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vencovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wikman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">P</forename><surname>Seelig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bgm</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Van Venrooij</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="116" to="123" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Incidence of malignant disease in biopsy-proven inflammatory myopathy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Buchbinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Dennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Giles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="1087" to="1095" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Prednisone and azathioprine for polymyositis: long-term follow up</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Bunch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="45" to="48" />
			<date type="published" when="1981">1981</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Azathioprine with prednisone for polymyositis: a controlled, clinical trial</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Bunch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Worthington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Coombs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Ilstrup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page" from="365" to="369" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Callen</surname></persName>
		</author>
		<author>
			<persName><surname>Dermatomyositis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="53" to="57" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Penicillamine induced polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Carroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Will</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Peter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Dawkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="995" to="999" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases</title>
		<author>
			<persName><forename type="first">V</forename><surname>Chaudhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Cornblath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Griffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Drachman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="94" to="96" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Shen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="page" from="825" to="831" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cherin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wechsler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Piette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bletry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coutellier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ziza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Godeau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="162" to="168" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cherin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Piette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wechsler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bletry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ziza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Laraki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Godeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1092" to="1097" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cherin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Menard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mouton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Viallard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lehello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Authier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gherardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Coquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Leroi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="452" to="457" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cherin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pelletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Laforet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Genereau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Maisonobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Eymard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="467" to="474" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Intravenous immunoglobulin for dysphagia of inclusion body myositis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Cherin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pelletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Teixeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Laforet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Eymard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="326" to="327" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Treatment of dermatomyositis and polymyositis</title>
		<author>
			<persName><forename type="first">Ehs</forename><surname>Choy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Isenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="7" to="13" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil for myasthenia gravis: an open-label pilot study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Ciafaloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Massey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tucker-Lipsomb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Sanders</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="97" to="99" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Campion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bohan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Paulus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="62" to="71" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">P</forename><surname>Confalonieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Megna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galbiati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cornelio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="164" to="169" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cronin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin North Am</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="655" to="665" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Cronin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="1225" to="1228" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Simple method for measurement of lower extremity muscle strength</title>
		<author>
			<persName><forename type="first">M</forename><surname>Csuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mccarty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="77" to="81" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Inclusion body myositis in HIV-1 and HTLV-1 infected patients</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Cupler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leon-Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Semino-Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="1887" to="1893" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Inclusion body myositis mimicking motor neuron disease</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dabby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lange</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Trojaborg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Hays</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Lovelace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Brannagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Rowland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1253" to="1256" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Polymyositis, dermatomyositis and inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="page" from="1487" to="1498" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Inflammatory and toxic myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol Neurosurg</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="645" to="654" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Retroviruses and inflammatory myopathies in humans and primates</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Baillieres Clin Neurol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="659" to="691" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Controlled studies of high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="S37" to="S45" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Molecular immunology and genetics of inflammatory muscle diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1509" to="1512" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Progress in inflammatory myopathies: good but not good enough</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="569" to="573" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Illa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dambrosia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Soueidan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Otero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Dinsmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mccrosky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">329</biblScope>
			<biblScope unit="page" from="1993" to="2000" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Illa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gallardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Juarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="100" to="104" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Treatment of inclusion-body myositis with IVIg: a double-blind placebo-controlled study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sonies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dambrosia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sekul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cupler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="712" to="716" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fujii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spector</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cupler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="323" to="327" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Inclusion body myositis associated with systemic sarcoidosis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Danon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">H</forename><surname>Perurena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ronan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Manaligod</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Can J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="334" to="336" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Antiendothelial cell antibodies in inflammatory myopathies: distribution among clinical and serologic groups and association with interstitial lung disease</title>
		<author>
			<persName><forename type="first">D'</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Keser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Khamashta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Direskeneli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Targoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grv</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="161" to="164" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy</title>
		<author>
			<persName><forename type="first">De</forename><surname>Bleeker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="369" to="376" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Cytokines and chemokines are both expressed by human myoblasts: possible relevance for the immune pathogenesis of muscle inflammation</title>
		<author>
			<persName><forename type="first">De</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Baggi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>De Waal Malefyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1329" to="1335" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Cardiac involvement in polymyositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Denbow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Lie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Tancredi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Bunch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1088" to="1092" />
			<date type="published" when="1979">1979</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Neurological complications of Wegener&apos;s granulomatosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Drachman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="145" to="155" />
			<date type="published" when="1963">1963</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Interferon beta-1a treatment of corticosteroid sensitive polymyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Dressell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Beuche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page">676</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy</title>
		<author>
			<persName><forename type="first">I</forename><surname>Eisenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Avidan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Potikha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hochner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Olender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Barash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shemesh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Grabov-Nardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shmilevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Friedmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Bradley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Baumbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lancet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Asher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Beckmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Argov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mitrani-Rosenbaum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="83" to="87" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Induction of interleukin 2 messenger RNA inhibited by cyclosporin A</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Mizel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spector</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cupler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page" from="1439" to="1441" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Microvascular changes in early and advanced dermatomyositis: a quantitative study</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Emslie-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="343" to="358" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Necrotizing myopathy with pipe-stem capillaries, microvascular deposition of the complement membrane attack complex (MAC) and minimal cellular infiltration</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Emslie-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="936" to="939" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Inflammatory myopathies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Q</forename><surname>Banker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Myology</title>
				<editor>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><surname>Franzini-Armstrong</surname></persName>
		</editor>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>McGraw-Hill</publisher>
			<date type="published" when="1994">1994</date>
			<biblScope unit="page" from="1335" to="1383" />
		</imprint>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Treatment of inclusion body myositis and hereditary inclusion body myopathy with reference to pathogenic mechanisms: personal experience</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion body myositis and myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">C</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="351" to="382" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Resistive exercise in the rehabilitation of polymyositis/dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Escalante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Beardmore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1340" to="1344" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Recent advances in the management of adult myositis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Fam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Invest Drugs</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1265" to="1277" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Expression of TNF-alpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">O</forename><surname>Fedczyna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lutz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Pachman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">200</biblScope>
			<biblScope unit="page" from="236" to="239" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">E</forename><surname>Feist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dorner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kuckelkorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Schmidtke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Micheel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hiepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Burmester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Kloetzel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="1313" to="1318" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Myositis following treatment with high-dose interleukin-2 for malignancy</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Finger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Heywood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="752" to="753" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Follansbee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Zerbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Taj</forename><surname>Medsger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="194" to="198" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Foote</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Kimbrough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><surname>Lupus Myositis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="65" to="68" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Magnetic resonance imaging in the idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Frank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dakalas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1693" to="1700" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Limited T-cell receptor V gene usage in inclusion body myositis</title>
		<author>
			<persName><forename type="first">I-M</forename><surname>Fyhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A-R</forename><surname>Moslemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tarkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Immunol</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="109" to="114" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Bartoccioni E. Myoblasts produce IL-6 in response to inflammatory stimuli</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gallucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Provenzano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mazzarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Scuderi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="267" to="273" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Genetics of idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="514" to="520" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Autoantibodies in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med Sci</title>
		<imprint>
			<biblScope unit="volume">319</biblScope>
			<biblScope unit="page" from="227" to="233" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">HLA associations with inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Laing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ollier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="40" to="45" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Antigen processing and presentation by a murine myoblast cell line</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chen</forename><forename type="middle">W</forename><surname>Tabarias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bains</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mc-Cluskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="614" to="619" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Apolipoprotein Ee4 in inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tabarias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Van Bockxmeer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Laing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="957" to="959" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Genetic factors in sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Blechynden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tabarias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Inclusion body myositis and myopathies</title>
				<editor>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">G</forename><surname>Serratrice</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</editor>
		<meeting><address><addrLine>Cambridge</addrLine></address></meeting>
		<imprint>
			<publisher>Cambridge University Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="177" to="185" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil in the treatment of severe skin manifestation of dermatomyositis: a series of four cases</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Gelber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Nousari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Wigley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="1542" to="1545" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Intermittent, high dose, intravenous glucocorticoid (GC) treatment (Rx) is preferred to high dose oral GC administration in adult dermatomyositis (DM)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Genge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page">A321</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Macrophagic myofasciitis: an emerging entity</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gherardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Coquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cherin</forename><forename type="middle">P</forename><surname>Authier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Laforet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Belec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mussini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pellissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Fardeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">352</biblScope>
			<biblScope unit="page" from="347" to="352" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Macrophagic myofasciitis lesions assess long-term persistence of vaccinederived aluminium hydroxide in muscle</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Gherardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Coquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cherin</forename><forename type="middle">P</forename><surname>Belec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Moretto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dreyfus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Pellissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Chariot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Authier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="1821" to="1831" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Ginn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Wilder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mbauya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="400" to="405" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Polymyositis associated with simvastatin</title>
		<author>
			<persName><forename type="first">N</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sensi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mattii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Battisti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Villanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gennari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page" from="1600" to="1601" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Differential expression of perforin in muscleinfiltrating T-cells in polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Engelhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pongratz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wekerle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tschopp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jenne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="2905" to="2910" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">High dose intravenous immunoglobulin (IVIg) in dermatomyositis: clinical responses and effect on sIL-2R levels</title>
		<author>
			<persName><forename type="first">I</forename><surname>Gottfried</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seeber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Anegg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rieger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stingl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Volc-Platzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Dermatol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="29" to="35" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Grau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Miro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pedrol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Casademont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Masanes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Haussman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Urbano</forename><forename type="middle">-</forename><surname>Marquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1921" to="1926" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">The pathogenesis of dermatomyositis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="21" to="22" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Inclusion body myositis and myopathies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dimauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Rowland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="705" to="713" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Dermatomyositis-like syndrome induced by nonsteroidal anti-inflammatory agents</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Grob</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Collet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Bonerandi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatologica</title>
		<imprint>
			<biblScope unit="volume">178</biblScope>
			<biblScope unit="page" from="58" to="59" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function</title>
		<author>
			<persName><forename type="first">Tjddacs</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="2213" to="2219" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Randomized pilot trial of beta INF1a (Avonex) in patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">Tms</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1566" to="1570" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Scleromyxedema and inflammatory myopathy: a clinicopathologic study of three patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Harvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Ojeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Cheah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Aust NZ J Med</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="329" to="335" />
			<date type="published" when="1986">1986</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Scleromyositis a distinctive overlap syndrome</title>
		<author>
			<persName><forename type="first">I</forename><surname>Hausmanowa-Petrusewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blaszczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kowalska-Oledzka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jablonska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Myol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="201" to="204" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Cyclosporin in juvenile dermatomyositis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Heckmatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Saunders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cambridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Hyde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dubowitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1063" to="1066" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Anti-TNF blockade with Infliximab in polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Van Den Hoogen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barrera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Netea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lvp</forename><surname>Nijmegan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">S193</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy</title>
		<author>
			<persName><forename type="first">Gjd</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bgm</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ter</forename><surname>Laak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Gabreels-Feston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aawm</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">415</biblScope>
			<biblScope unit="page" from="882" to="884" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone</title>
		<author>
			<persName><forename type="first">Gjd</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ter</forename><surname>Laak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bgm</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="702" to="710" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Polymyositis and dermatomyositis 1990 -diagnosis, treatment and prognosis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Henricksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lindvall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog Neurobiol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="181" to="193" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Polymyositis-treatment and prognosis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Henricksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sandstedt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neurol Scand</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="280" to="300" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Granulomatous myositis, primary biliary cirrhosis, pancytopenia, and thymoma</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Hermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Blaivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Wald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Feldman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1133" to="1136" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Hertzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">L</forename><surname>Blevins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Greenfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Gleich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">322</biblScope>
			<biblScope unit="page" from="869" to="873" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Frequency of specific cancer types in dermatomyositis and polymyositis: a populationbased study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sigurgeirsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pukkala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mellemkjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Airio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Felson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">357</biblScope>
			<biblScope unit="page" from="96" to="100" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Interstitial lung disease in polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hirakata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nagai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="501" to="508" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Cellular immune mechanisms in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Goebels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Behrens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="520" to="526" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Autoimmune diseases of muscle</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Hollingsworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Dawkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">The autoimmune diseases</title>
				<editor>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Rose</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">I</forename><surname>Mackay</surname></persName>
		</editor>
		<meeting><address><addrLine>San Diego</addrLine></address></meeting>
		<imprint>
			<publisher>Academic Press</publisher>
			<date type="published" when="1998">1998</date>
			<biblScope unit="page" from="663" to="686" />
		</imprint>
	</monogr>
	<note>3rd ed</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Thigh muscle mass and function in patients treated with glucocorticoids</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Horber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Schiedegger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Grunig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Frey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="302" to="307" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Dysphagia in patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Houser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Calabrese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Strome</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Laryngoscope</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="1001" to="1005" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="621" to="624" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisolone, azathioprine and methotrexate and a comparison of their efficacy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Joffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Targoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Highs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="379" to="387" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">A functional index in myositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Josefson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Romanus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Carlsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1380" to="1384" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Electrophysiological spectrum of inclusion body myositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Joy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Baysal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="949" to="951" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">The role of cytokines in polymyositis: interferon-gamma induces class II and enhances class I major histocompatibility complex antigen expression on cultured human muscle cells</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Kalovidouris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Lab Clin Med</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="244" to="251" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Synergistic cytotoxic effect of interferon-gamma and tumour necrosis factor-alpha on cultured human muscle cells</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Kalovidouris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Plotkin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">322</biblScope>
			<biblScope unit="page" from="1698" to="1703" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Drug treatment of lipid disorders</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Knopp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">341</biblScope>
			<biblScope unit="page" from="498" to="511" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Dexamethasone (DEX) induces transcription of glutamine synthetase (GS) in human muscle in vitro: a possible explanation of steroid-induced muscle atrophy (&quot;steroid myopathy&quot;)</title>
		<author>
			<persName><forename type="first">B</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Amemiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Leon-Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dakalas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page">A321</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myositis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Simonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stroncek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="139" to="142" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Mapping of a candidate region for susceptibility to inclusion body myositis in the human major histocompatibility complex</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Croager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Witt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kiers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunogenetics</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="508" to="516" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Mitochondrial DNA variants in inclusion body myositis and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gaudieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kiers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Garlepp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="604" to="611" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Kovacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Kovacs</surname></persName>
		</author>
		<author>
			<persName><surname>Dermatomyositis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="899" to="920" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Procainamide-induced lupus erythematosus</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Ladd</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">267</biblScope>
			<biblScope unit="page" from="1357" to="1358" />
			<date type="published" when="1962">1962</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Eosinophilic polymyositis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Layzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Shearn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Satya-Murti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="65" to="71" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">The treatment of inclusion body myositis : a retrospective review and a randomized, prospective trial of immunosuppressive therapy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="225" to="235" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Local expression of cytokines in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lepidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Frances</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Machado-Baeta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pellissier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathol Appl Neurobiol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="73" to="79" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">The role of lymphotoxin in pathogenesis in polymyositis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Inukai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kuru</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Doyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sobue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="521" to="527" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: peripheral nerve involvement. Combined morphological and electrophysiological studies on peripheral nerves</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hedstrom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="327" to="338" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bjorkander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neurol Scand</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="123" to="131" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Anti-thymocyte globulin treatment in inclusion body myositis: a randomised pilot study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Trysberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tarkowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">476</biblScope>
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">A</forename><surname>Liprandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Figarella-Branger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pellissier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lepidid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="642" to="648" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Targoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="360" to="374" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: no evidence for a neurogenic component</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Luciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dakalas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="29" to="33" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Cyclosporin in the management of polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Luek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Trend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Swash</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="304" to="305" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Rheumatol Rep</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="216" to="224" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Treatment and investigation of idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-L</forename><surname>Chung</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="7" to="17" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Ulfgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Nyberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Klareskog</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="865" to="874" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis?</title>
		<author>
			<persName><forename type="first">K</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Komuta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Igarashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="24" to="29" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">The benefits and limitations of a physical training program for patients with inflammatory myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Mahowald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Rheumatol Rep</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="317" to="324" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">The treatment of persistent severe idiopathic inflammatory myositis with anti-TNF therapy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Maillard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Nmr</forename><surname>Wilkinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Beresford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Murray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">S143</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mantegazza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bernasconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Confalonieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cornelio</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">244</biblScope>
			<biblScope unit="page" from="277" to="287" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Cyclosporin treatment in juvenile dermatomyositis: a review of 26 cases</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Manzur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Topaloglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jungbluth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dubowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Muntoni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">S150</biblScope>
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Marguerie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Bunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hlc</forename><surname>Beynon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jmb</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>So</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Walport</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Q J Med</title>
		<imprint>
			<biblScope unit="volume">282</biblScope>
			<biblScope unit="page" from="1019" to="1038" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">Pulmonary involvement in polymyositis and in dermatomyositis</title>
		<author>
			<persName><forename type="first">I</forename><surname>Marie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Hatron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hachulla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wallaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Michon-Pasturel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Devulder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1336" to="1343" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<monogr>
		<title level="m" type="main">Inflammatory diseases of muscle</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1988">1988</date>
			<publisher>Blackwell Scientific Publications</publisher>
			<biblScope unit="page">203</biblScope>
			<pubPlace>Oxford</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Treatment of autoimmune inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="507" to="509" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">Inflammatory myopathies: Part 1</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">J</forename><surname>Ojeda</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="215" to="227" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin North Am</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1" to="20" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Walton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Skeletal muscle pathology</title>
				<editor>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Walton</surname></persName>
		</editor>
		<meeting><address><addrLine>Edinburgh</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1992">1992</date>
			<biblScope unit="page" from="453" to="491" />
		</imprint>
		<respStmt>
			<orgName>Churchill Livingstone</orgName>
		</respStmt>
	</monogr>
	<note>2nd ed</note>
</biblStruct>

<biblStruct xml:id="b157">
	<monogr>
		<title level="m" type="main">Treatment of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Laing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<editor>Mastaglia FL</editor>
		<imprint>
			<date type="published" when="1993">1993</date>
			<publisher>Bailliere Tindell</publisher>
			<biblScope unit="page" from="717" to="740" />
			<pubPlace>London</pubPlace>
		</imprint>
	</monogr>
	<note>Inflammatory myopathies</note>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Treatment of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="651" to="664" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">Immunoglobulin therapy in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="107" to="110" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Inflammatory myopathy</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Treat Opt Neurol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="263" to="272" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">Relapses in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1160" to="1161" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis: clinical and genetic studies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Myol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">105</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Matsubara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Takamori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yokoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page">1008</biblScope>
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<monogr>
		<title level="m" type="main">Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with b-amyloid</title>
		<author>
			<persName><forename type="first">L</forename><surname>Meda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Prat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Scarpini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Scarlato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Cassatella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rossi</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>25-35</note>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="45" to="52" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">Skeletal muscle involvement in progressive systemic sclerosis (scleroderma)</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Rodnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moossy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Vester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="554" to="568" />
			<date type="published" when="1968">1968</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">The epidemiology of polymyositis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">N</forename><surname>Dawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Masi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="715" to="723" />
			<date type="published" when="1970">1970</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy</title>
		<author>
			<persName><forename type="first">M-A</forename><surname>Megens-De Letter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Van Doorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hfj</forename><surname>Savelkoul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Cytokine Netw</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="471" to="477" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">Granulomatous myositis and myopathy associated with Crohn&apos;s colitis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Menard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Haddad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Blain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Beaudry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Devroede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Masse</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">295</biblScope>
			<biblScope unit="page" from="818" to="819" />
			<date type="published" when="1976">1976</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">The immunopathogenic role of complement in human muscle disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Garcha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Kissel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol Neurosurg</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="226" to="234" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA DR beta chain</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mierau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bartz-Bazzanella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Genth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="868" to="876" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">Randomised double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy</title>
		<author>
			<persName><forename type="first">F</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saminaden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Lecky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Winer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">199</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">S53</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main">Myositis-specific autoantibodies: touchstones for understanding the inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="1846" to="1849" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main">Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Rider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y-L</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Danko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Farewell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Oakley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Oakley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pilkington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vencovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vincent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Isenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1262" to="1273" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main">Structures targeted by the immune system in myositis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mimori</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="521" to="527" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main">Relapses in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">O</forename><surname>Miro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Laguna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Grau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1159" to="1160" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main">HTLV-1 and polymyositis in Jamaica</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">S</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rodgers-Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Char</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1454" to="1455" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main">Mycophenolate (Cell-Cept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mowzoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sussman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Bradley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="page" from="119" to="122" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main">Clinical correlates of granulomas in muscle</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mozaffar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lopate</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pestronk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">245</biblScope>
			<biblScope unit="page" from="519" to="524" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main">Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibers</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mozaffar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pestronk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="472" to="478" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main">Long-lasting effectiveness of intravenous immunoglobulin in a patient with inclusion-body myositis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Mukunda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page">1156</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title level="a" type="main">The first case of polymyositis associated with interferon therapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mutsuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Abe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yonezawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Akahonai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kurokawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hayashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intern Med</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="806" to="808" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main">A variety of cytokines and immunologically relevant surface molecules are expresssed by normal skeletal muscle cells under proinflammatory stimuli</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Merritt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kirk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="407" to="414" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main">A case of inclusion body myositis with benign monoclonal gammopathy successfully responding by repeated immunoabsorption</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nakayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Horiuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Murayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nakase</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="230" to="233" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main">Idiopathic giant cell polymyositis: report of a case and review of the syndrome</title>
		<author>
			<persName><forename type="first">T</forename><surname>Namba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Brunner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Grob</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="27" to="30" />
			<date type="published" when="1974">1974</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main">Corticosteroid resistant interstitial pneumonitis in dermatomyositis/ polymyositis: prediction and treatment with cyclosporine</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Nawata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kurasawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takabayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Miike</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hiraguri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kawai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Iwamoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1527" to="1533" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main">Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results?</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nzeusseu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Brion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lefebvre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Knoops</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Devogelaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Houssiau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="441" to="446" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title level="a" type="main">Successful use of Infliximab in a case of refractory juvenile dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nzeusseu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Durez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Houssain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Devogelaer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page">S90</biblScope>
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b189">
	<analytic>
		<title level="a" type="main">Current approach to the treatment of polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Oddis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="492" to="497" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b190">
	<analytic>
		<title level="a" type="main">Incidence of polymyositis-dermatomyositis: a 20 year study of hospital diagnosed cases in Allegheny County, PA 1963-1982</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Oddis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Conte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Steen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1329" to="1334" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b191">
	<analytic>
		<title level="a" type="main">Serum autoantibody to the nucleolar antigen PM-Scl: clinical and immunogenetic associations</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Oddis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Okano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Rudert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trucco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Duquesnoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1211" to="1217" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b192">
	<analytic>
		<title level="a" type="main">Tacrolimus in refractory polymyositis with interstitial lung disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Oddis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Sciurba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Elmagd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Starzl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="1762" to="1763" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b193">
	<analytic>
		<title level="a" type="main">The ab T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>O'hanlon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Autoimmun</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="321" to="333" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b194">
	<analytic>
		<title level="a" type="main">Inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="527" to="533" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b195">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Orth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Tabrizi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ahv</forename><surname>Schapira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page">1235</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b196">
	<analytic>
		<title level="a" type="main">Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Pachman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Hayford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Daugherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pallansch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Gweanter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jerath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sinacore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Szer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Dyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Hochberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1198" to="1204" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b197">
	<analytic>
		<title level="a" type="main">TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumour necrosis factor alpha, disease duration, and pathologic calcifications</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Pachman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Liotta-Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Kensella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Mendez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Kinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="2368" to="2377" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b198">
	<analytic>
		<title level="a" type="main">Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Olsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Rheumatol Rep</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="334" to="345" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b199">
	<analytic>
		<title level="a" type="main">Incidence of inflammatory myopathies in Victoria, Australia, and evidence of spatial clustering</title>
		<author>
			<persName><forename type="first">M</forename><surname>Patrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Buchbinder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jolley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Dennett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Buchanan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1094" to="1100" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b200">
	<analytic>
		<title level="a" type="main">Features of polymyositis and dermatomyositis in the elderly: a case-control study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Pautas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cherin</forename><forename type="middle">P</forename><surname>Piette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Pelletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wechsler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cabane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="241" to="244" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b201">
	<analytic>
		<title level="a" type="main">Disease progression in sporadic inclusion body myositis: observations in 78 patients</title>
		<author>
			<persName><forename type="first">Abs</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Malley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="296" to="298" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b202">
	<analytic>
		<title level="a" type="main">Nasopharyngeal carcinoma with dermatomyositis: analysis of 12 cases</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Sheem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Hzu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Otolaryngol Head Neck Surg</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="1298" to="1301" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b203">
	<analytic>
		<title level="a" type="main">Exercise therapy in patients with myopathy</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="547" to="552" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b204">
	<analytic>
		<title level="a" type="main">Freqency of relapses in patients with polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1668" to="1672" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b205">
	<analytic>
		<title level="a" type="main">Prevalence of sporadic inclusion body myositis in Western Australia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="970" to="972" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b206">
	<analytic>
		<title level="a" type="main">Patterns of muscle involvement in sporadic inclusion body myositis. A clinical and MRI study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Cala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Thickbroom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Melsom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1526" to="1534" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b207">
	<analytic>
		<title level="a" type="main">The effect of resisted exercise on muscle strength in patients with myopathy</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guthrie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Byrne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Sci</title>
		<imprint>
			<biblScope unit="volume">199</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">S46</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b208">
	<analytic>
		<title level="a" type="main">Seasonal occurrences of relapses in inflammatory myopathies: a preliminary study</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Garlepp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">249</biblScope>
			<biblScope unit="page" from="441" to="444" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b209">
	<analytic>
		<title level="a" type="main">Eosinophilic myopathic syndromes</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Pickering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Walport</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="504" to="510" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b210">
	<analytic>
		<title level="a" type="main">Granulomatous myositis: clinicopathologic study of 12 cases</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Prayson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="63" to="68" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b211">
	<analytic>
		<title level="a" type="main">Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment</title>
		<author>
			<persName><forename type="first">G</forename><surname>Ramirez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Asherson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Khamashta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cervera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D'</forename><surname>Cruz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="114" to="120" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b212">
	<analytic>
		<title level="a" type="main">Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Reiff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Rawlings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shaham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Franke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Richardson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Szer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Bernstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2436" to="2443" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b213">
	<analytic>
		<title level="a" type="main">Muscle imaging in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Reimers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Finkenstaedt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="475" to="485" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b214">
	<analytic>
		<title level="a" type="main">Magnetic resonance imaging of skeletal muscles in idiopathic inflammatory myopathies of adults</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Reimers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schedel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Fleckenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nagele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Witt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Pongratz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Vogl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">241</biblScope>
			<biblScope unit="page" from="306" to="314" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b215">
	<analytic>
		<title level="a" type="main">Sjogren&apos;s syndrome and polymyositis or dermatomyositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Ringel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Z</forename><surname>Forstot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Butcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="157" to="163" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b216">
	<analytic>
		<title level="a" type="main">Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Walton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="747" to="768" />
			<date type="published" when="1966">1966</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b217">
	<analytic>
		<title level="a" type="main">A prospective natural history study of inclusion body myositis: implications for clinical trials</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Mcdermott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Thornton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Palenski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">B</forename><surname>Martens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="548" to="550" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b218">
	<analytic>
		<title level="a" type="main">A pilot randomized trial of oxandrolone in inclusion body myositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Rutkove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Nardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Felice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Raynor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1081" to="1087" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b219">
	<analytic>
		<title level="a" type="main">Etanercept is effective in the treatment of polymyositis/dermatomyositis which is refractory to conventional therapy including steroids and other disease modifying agents</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Saadeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page">S193</biblScope>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b220">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: analysis of 32 cases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Sayers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Calabrese</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1385" to="1389" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b221">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil in the therapy of refractory polymyositis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schafers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Tokya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="286" to="288" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b222">
	<analytic>
		<title level="a" type="main">Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Sekul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dakalas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="863" to="866" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b223">
	<analytic>
		<title level="a" type="main">Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Selva-O'callaghan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sanchez-Sitjes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Munoz-Gall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mijares-Boeckh-</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Solans-Laque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Angel</forename><surname>Bosch-Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Morrell-Brotad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Vilardell-Tarres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="914" to="916" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b224">
	<analytic>
		<title level="a" type="main">Update on the genetics of the idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Shamim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Rider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="482" to="491" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b225">
	<analytic>
		<title level="a" type="main">Mixed connective tissue disease-apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">C</forename><surname>Sharp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Irvin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Gould</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Holman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="148" to="159" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b226">
	<analytic>
		<title level="a" type="main">Diffuse fasciitis with eosinophilia: a new syndrome?</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Shulman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trans Assoc Am Physicians</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="70" to="86" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b227">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis and hereditary inclusion body myopathy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Simmons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Towfighi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Neuromuscul Dis</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="122" to="132" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b228">
	<analytic>
		<title level="a" type="main">Treatment of inclusion body myositis with high-dose intravenous immunoglobulin</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Souedin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dakalas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="876" to="879" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b229">
	<analytic>
		<title level="a" type="main">Safety and efficacy of strength training in patients with sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Spector</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Lemmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Fleisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Feuerstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Hurley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1242" to="1248" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b230">
	<analytic>
		<title level="a" type="main">Dermatomyositis with normal muscle enzyme concentrations. A single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Stonecipher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Jorizzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Monu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Sutej</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">130</biblScope>
			<biblScope unit="page" from="1294" to="1299" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b231">
	<analytic>
		<title level="a" type="main">Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15 and monocyte chemoattractant protein-1 production</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sugiura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kawaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Harigai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takagi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ohta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fukasawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kamatani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">164</biblScope>
			<biblScope unit="page" from="6593" to="6600" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b232">
	<analytic>
		<title level="a" type="main">Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Sultan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ioannou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Isenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="22" to="26" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b233">
	<analytic>
		<title level="a" type="main">Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids</title>
		<author>
			<persName><forename type="first">B</forename><surname>Tabarki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ponsot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Prieur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tardieu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pediatr Neurol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="205" to="211" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b234">
	<analytic>
		<title level="a" type="main">Classification criteria for polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Tanimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ueki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nishitani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kiuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ohashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="668" to="674" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b235">
	<analytic>
		<title level="a" type="main">Update on myositis-specific and myositis-associated autoantibodies</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Targoff</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="475" to="481" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b236">
	<analytic>
		<title level="a" type="main">Classification criteria for the idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Targoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Oddis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="527" to="535" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b237">
	<analytic>
		<title level="a" type="main">Interstitial lung disease in polymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Tazelaar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Viggiano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pickersgill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Colby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Rev Respir Dis</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="727" to="733" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b238">
	<analytic>
		<title level="a" type="main">Selective depletion of lymphoid tissue by cyclophosphamide</title>
		<author>
			<persName><forename type="first">L</forename><surname>Turk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Poulder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="285" to="296" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b239">
	<analytic>
		<title level="a" type="main">HMG-CoA reductase inhibitors and myotoxicity</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ucar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mjorndal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dahlqvist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drug Saf</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="441" to="457" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b240">
	<analytic>
		<title level="a" type="main">Oral pulsed high-dose dexamethasone for myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Van Der Meulen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hoogendijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Wokke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Visser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">247</biblScope>
			<biblScope unit="page" from="102" to="105" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b241">
	<analytic>
		<title level="a" type="main">Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Vencovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jarosova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Machacek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Studynkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kafkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bartunkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nemcova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Charvat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="95" to="102" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b242">
	<analytic>
		<title level="a" type="main">Update on therapy for refractory dermatomyositis and polymyositis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Villalba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Adams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="544" to="551" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b243">
	<analytic>
		<title level="a" type="main">Treatment of refractory myositis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Villaba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Sherman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Gourley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Thornton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Burgess</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="392" to="399" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b244">
	<analytic>
		<title level="a" type="main">A search for genetic influence in idiopathic inflammatory myopathy</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Walker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Roberts</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neurol Scand</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="432" to="443" />
			<date type="published" when="1982">1982</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b245">
	<analytic>
		<title level="a" type="main">High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lochmuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toepfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schlotter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reilich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Muller-Felber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pongratz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">247</biblScope>
			<biblScope unit="page" from="22" to="28" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b246">
	<analytic>
		<title level="a" type="main">Ovarian cancer in patients with dermatomyositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Whitmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Rosenshein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Provost</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="153" to="160" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b247">
	<analytic>
		<title level="a" type="main">Dermatomyositis sine myositis: association with malignancy</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Whitmore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>Rosenshein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Provost</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="101" to="105" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b248">
	<analytic>
		<title level="a" type="main">Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Wiesinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quittan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Aringer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Seeber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Volc-Platzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smolen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Graninger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="196" to="200" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b249">
	<analytic>
		<title level="a" type="main">Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Wiesinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Quittan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nuhr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Volc-Platzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ebenbichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zehetgruber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Graninger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Phys Med Rehabil</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b250">
	<analytic>
		<title level="a" type="main">Laboratory testing of muscle function in the management of neuromuscular disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Wiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nichlin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="384" to="387" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b251">
	<analytic>
		<title level="a" type="main">Padberg GW. Dysphagia in inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Wintzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gtam</forename><surname>Bots</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>De Bakker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Hulshof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="1542" to="1545" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b252">
	<analytic>
		<title level="a" type="main">The association of malignancy with myositis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yazici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Kagen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="498" to="500" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b253">
	<analytic>
		<title level="a" type="main">The overall and temporal association of cancer with polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Zantos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Felson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1855" to="1859" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b254">
	<analytic>
		<title level="a" type="main">Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases</title>
		<author>
			<persName><forename type="first">V</forename><surname>Zeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Prieur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guillevin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1424" to="1427" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b255">
	<monogr>
		<title level="m" type="main">Myopathy in connective tissue disease other than polymyositis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<editor>Mastaglia FL</editor>
		<imprint>
			<date type="published" when="1988">1988</date>
			<publisher>Blackwell Scientific Publications</publisher>
			<biblScope unit="page" from="107" to="124" />
			<pubPlace>Oxford</pubPlace>
		</imprint>
	</monogr>
	<note>Inflammatory diseases of muscle</note>
</biblStruct>

<biblStruct xml:id="b256">
	<analytic>
		<title level="a" type="main">Idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Zilko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Mastaglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BioDrugs</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="262" to="272" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
